Peer-influenced content. Sources you trust. No registration required. This is HCN.

The New England Journal of MedicineSingle-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression

In this phase 2 double-blind trial, adults with treatment-resistant depression were randomly assigned to receive psychological support and a single dose of a proprietary, synthetic form of psilocybin at a dose of 25 mg, 10 mg, or 1 mg (control). The Montgomery-Sberg Depression Rating Scale (MADRS) total score change from baseline to week three was the main outcome measure. Secondary endpoints included remission at week 3, response at week 3, and sustained response at 12 weeks.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form